Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Lees

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Current Medical Research and Opinion|September 10, 2010
Clinical burden of venous thromboembolismAndras Ruppert, Michael Lees, Thomas Steinle
Journal of Medical Economics|January 13, 2011
Economic burden of venous thromboembolism: a systematic reviewAndras Ruppert, Thomas Steinle, Michael Lees
Patterns (New York, N.Y.)|December 24, 2021
The non-linear impact of data handling on network diffusion modelsJames Nevin, Michael Lees, Paul Groth
Peerj. Computer Science|June 26, 2025
The effects of mismatched train and test data cleaning pipelines on regression models: lessons for practiceJames Nevin, Michael Lees, Paul Groth
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2011
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxabanRichard J Friedman, Nishan Sengupta, Michael Lees
Behavior Research Methods|July 15, 2015
The influence of memory on indoor environment exploration: A numerical studyVaisagh Viswanathan, Michael Lees, Peter M A Sloot
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2014
Quantifying the burden of informal caregiving for patients with cancer in EuropeAmir Goren, Isabelle Gilloteau, Michael Lees, et al.
F1000Research|October 27, 2018
Time to really share real-world data?Sophie Graham, Laura McDonald, Radek Wasiak, et al.
Journal of Gastroenterology and Hepatology|April 23, 2002
Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial dataSteven Crowley, David Tognarini, Paul Desmond, et al.
Journal of Medical Economics|October 26, 2011
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Current Medical Research and Opinion|September 10, 2010
Clinical burden of venous thromboembolismAndras Ruppert, Michael Lees, Thomas Steinle
Journal of Medical Economics|January 13, 2011
Economic burden of venous thromboembolism: a systematic reviewAndras Ruppert, Thomas Steinle, Michael Lees
Patterns (New York, N.Y.)|December 24, 2021
The non-linear impact of data handling on network diffusion modelsJames Nevin, Michael Lees, Paul Groth
Peerj. Computer Science|June 26, 2025
The effects of mismatched train and test data cleaning pipelines on regression models: lessons for practiceJames Nevin, Michael Lees, Paul Groth
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2011
Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxabanRichard J Friedman, Nishan Sengupta, Michael Lees
Behavior Research Methods|July 15, 2015
The influence of memory on indoor environment exploration: A numerical studyVaisagh Viswanathan, Michael Lees, Peter M A Sloot
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 6, 2014
Quantifying the burden of informal caregiving for patients with cancer in EuropeAmir Goren, Isabelle Gilloteau, Michael Lees, et al.
F1000Research|October 27, 2018
Time to really share real-world data?Sophie Graham, Laura McDonald, Radek Wasiak, et al.
Journal of Gastroenterology and Hepatology|April 23, 2002
Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial dataSteven Crowley, David Tognarini, Paul Desmond, et al.
Journal of Medical Economics|October 26, 2011
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspectiveAurea Duran, Nishan Sengupta, Alexander Diamantopoulos, et al.
Pageof 4